Cytek Biosciences (CTKB) Net Cash Flow Growth (1y) (2021 - 2026)
Cytek Biosciences (CTKB) Net Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.01 Bn | 175.72 Bn | 6.27 Bn | -53.07% |
| 2 | Stryker | 128.76 Bn | 125.88 Bn | 3.81 Bn | 17.60% |
| 3 | Medtronic | 108.90 Bn | 99.68 Bn | 6.41 Bn | 10.50% |
| 4 | Boston Scientific | 68.43 Bn | 66.98 Bn | 3.61 Bn | -283.58% |
| 5 | Edwards Lifesciences | 47.96 Bn | 44.29 Bn | 1.29 Bn | -564.44% |
| 6 | GE HealthCare Technologies | 28.29 Bn | 26.01 Bn | 1.98 Bn | -394.13% |
| 7 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | -31.84% |
| 8 | Smith & Nephew | 26.89 Bn | 26.31 Bn | - | - |
| 9 | Koninklijke Philips | 25.44 Bn | 22.31 Bn | 2.07 Bn | 76.43% |
| 10 | Cytek Biosciences | 563.08 Mn | 497.38 Mn | 21.25 Mn | -1,064.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,064.74% |
| Dec 31, 2025 | 94.10% |
| Sep 30, 2025 | 215.61% |
| Jun 30, 2025 | -390.21% |
| Mar 31, 2025 | -1,105.43% |
| Dec 31, 2024 | -1,449.00% |
| Sep 30, 2024 | -147.93% |
| Jun 30, 2024 | 4,076.28% |
| Mar 31, 2024 | 99.89% |
| Dec 31, 2023 | 111.76% |
| Sep 30, 2023 | 460.17% |
| Jun 30, 2023 | 101.39% |
| Mar 31, 2023 | -8,656.12% |
| Dec 31, 2022 | -219.70% |
| Sep 30, 2022 | -103.92% |
| Jun 30, 2022 | -26.14% |
| Mar 31, 2022 | -195.56% |
| Dec 31, 2021 | -109.78% |
| Sep 30, 2021 | 43,113.35% |